Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RLAY

Relay Therapeutics Inc

Dec 13 • 12:22PM ET

4.64

Dollar change -0.14
Percentage change -3.03	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX NTLA BEAM CRSP BLUE EDIT BMRN ADPT SGMO IONQ

| Held by: VTI VB IWM VBK VXF XBI IWN IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.61	Insider Own	26.36%	Shs Outstand	166.89M	Perf Week	0.54%
Market Cap	775.82M	Forward P/E	-	EPS next Y	-2.64	Insider Trans	-0.40%	Shs Float	123.26M	Perf Month	-20.22%
Income	-345.20M	PEG	-	EPS next Q	-0.57	Inst Own	73.16%	Short Float	9.68%	Perf Quarter	-42.85%
Sales	10.01M	P/S	77.50	EPS this Y	9.80%	Inst Trans	37.68%	Short Ratio	6.22	Perf Half Y	-36.59%
Book/sh	5.03	P/B	0.92	EPS next Y	-4.75%	ROA	-37.58%	Short Interest	11.93M	Perf Year	-54.02%
Cash/sh	5.02	P/C	0.92	EPS next 5Y	-	ROE	-42.69%	52W Range	4.25 - 12.14	Perf YTD	-57.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-38.74%	ROI	-39.09%	52W High	-61.82%	Beta	1.59
Dividend TTM	-	Quick Ratio	18.42	Sales past 5Y	319.82%	Gross Margin	44.99%	52W Low	9.06%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	18.42	EPS Y/Y TTM	2.55%	Oper. Margin	-3946.81%	RSI (14)	41.82	Volatility	8.64% 6.62%
Employees	323	Debt/Eq	0.06	Sales Y/Y TTM	-61.21%	Profit Margin	-3449.58%	Recom	1.23	Target Price	21.45
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-16.83%	Payout	-	Rel Volume	0.64	Prev Close	4.78
Sales Surprise	-100.00%	EPS Surprise	18.38%	Sales Q/Q	-100.00%	Earnings	Nov 06 AMC	Avg Volume	1.92M	Price	4.64
SMA20	-1.20%	SMA50	-17.53%	SMA200	-33.06%	Trades		Volume	574,890	Change	-3.03%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-24	Upgrade	Jefferies	Hold → Buy	$10.60 → $16
Sep-10-24	Resumed	Goldman	Buy	$20
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight	$15
Apr-20-23	Upgrade	Jefferies	Underperform → Hold	$12.50
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy	$29
Apr-13-23	Initiated	Raymond James	Outperform	$29
Feb-03-23	Initiated	Oppenheimer	Outperform	$33
Sep-30-22	Initiated	Barclays	Equal Weight	$23
Sep-02-22	Initiated	Stifel	Buy	$40
Jun-06-22	Initiated	Jefferies	Underperform	$13
Feb-01-22	Initiated	Berenberg	Buy	$45
Jul-21-21	Initiated	BofA Securities	Buy	$50
Dec-15-20	Reiterated	H.C. Wainwright	Buy	$54 → $57
Dec-08-20	Initiated	JMP Securities	Mkt Outperform	$66
Nov-05-20	Initiated	H.C. Wainwright	Buy	$54
Aug-10-20	Initiated	JP Morgan	Neutral	$36
Aug-10-20	Initiated	Guggenheim	Buy	$48
Aug-10-20	Initiated	Goldman	Buy	$64
Aug-10-20	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-11-24 06:00AM	Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival (GlobeNewswire) +12.42%
Dec-09-24 04:05PM	Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -5.74%
Dec-06-24 09:35AM	After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) (Zacks) +7.71%
Dec-05-24 06:51AM	Relay Therapeutics price target lowered to $18 from $19 at Leerink (TipRanks)
Dec-04-24 04:36PM	Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
08:01AM	Loading…
Dec-03-24 08:01AM	Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire) -6.00%
08:00AM	Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire)
Nov-20-24 09:35AM	Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)
Nov-19-24 09:35AM	Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)
Nov-07-24 04:05PM	Relay Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 04:05PM	Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire) +5.04%
Oct-30-24 04:05PM	Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 (GlobeNewswire)
Sep-17-24 08:24AM	Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? (Zacks) -6.29%
Sep-11-24 06:46PM	Why Relay Therapeutics Plummeted by Nearly 14% Today (Motley Fool) -13.83%
Sep-10-24 08:21PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -5.36%
04:34PM	Loading…
Sep-09-24 04:34PM	Relay Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +52.40%
11:30AM	Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients (Benzinga)
08:07AM	Relay breast cancer drug shows potential in early trial (BioPharma Dive)
06:55AM	Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival (GlobeNewswire)
Sep-06-24 04:05PM	Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024 (GlobeNewswire)
Aug-06-24 04:05PM	Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire) -7.93%
Jul-30-24 04:05PM	Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024 (GlobeNewswire)
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jun-06-24 07:00AM	Relay Therapeutics Discloses Three New Programs at New Program & Platform Event (GlobeNewswire)
Jun-05-24 04:05PM	Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 (GlobeNewswire)
May-21-24 04:05PM	Relay Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.50%
May-13-24 08:30AM	Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 (GlobeNewswire)
May-10-24 10:01AM	Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target (MT Newswires)
May-06-24 08:57AM	Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating (MT Newswires)
May-02-24 09:55PM	RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +6.31%
05:55PM	Loading…
05:55PM	Relay Therapeutics Outperforms Revenue Expectations in Q1 2024 (GuruFocus.com)
05:40PM	Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-25-24 04:05PM	Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Relay Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-15-24 12:39PM	3 Precision Medicine Stocks That Could Benefit From the Industrys Rise (InvestorPlace)
Mar-13-24 09:55AM	Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect? (Zacks)
Feb-26-24 04:05PM	Relay Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High? (Zacks)
Feb-22-24 04:40PM	Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights (GuruFocus.com) -5.39%
04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-15-24 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024 (GlobeNewswire) +7.89%
10:00AM	Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
03:29AM	Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last? (Zacks)
Feb-01-24 04:05PM	Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-08-24 07:00AM	Relay Therapeutics Announces $30 Million Private Placement Financing (GlobeNewswire)
Jan-02-24 04:05PM	Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.67%
Nov-30-23 09:55AM	Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 189.21%: Read This Before Placing a Bet (Zacks)
Nov-14-23 09:55AM	Wall Street Analysts See a 202.33% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High? (Zacks) +7.13%
Nov-07-23 04:05PM	Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference (GlobeNewswire)
Nov-02-23 06:21PM	Relay Therapeutics Inc (RLAY) Reports Q3 2023 Financial Results: Revenue Surges to $25.2 Million (GuruFocus.com) +8.35%
04:05PM	Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-31-23 12:00PM	Top 12 Medical AI Companies (Insider Monkey) +5.94%
Oct-26-23 04:05PM	Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023 (GlobeNewswire) +5.32%
10:02AM	Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-12-23 04:05PM	Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors (GlobeNewswire) -11.02%
Sep-18-23 04:05PM	Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey) +7.93%
Aug-08-23 06:05PM	Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.71%
04:02PM	Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-01-23 04:05PM	Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023 (GlobeNewswire) -5.48%
May-25-23 05:01PM	Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008 (GlobeNewswire)
May-24-23 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-18-23 08:16AM	Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-04-23 07:25PM	Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-27-23 04:05PM	Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
10:03AM	Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-21-23 02:48PM	Analysts Are Upgrading These 10 Stocks (Insider Monkey)
Apr-20-23 02:20AM	4 big analyst picks: BofA ups composite decking stocks Azek, Trex \| Pro Recap (Investing.com)
Apr-19-23 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +6.28%
Apr-18-23 10:40AM	Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3K Mutations (GlobeNewswire) -36.22%
Apr-14-23 05:05AM	Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Apr-13-23 06:12PM	Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says (Benzinga) +13.80%
03:49PM	Get In Now. 7 Stocks That Are Set to Soar. (InvestorPlace)
Apr-07-23 07:44AM	Relay Therapeutics (NASDAQ:RLAY) shareholders are up 13% this past week, but still in the red over the last year (Simply Wall St.)
Apr-06-23 09:55AM	Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before Placing a Bet (Zacks)
Mar-06-23 07:30AM	Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR (GlobeNewswire)
Mar-01-23 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-25-23 07:31AM	Relay Therapeutics Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Feb-23-23 05:45PM	Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-21-23 10:00AM	Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -5.26%
Feb-16-23 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) -5.01% +5.73%
10:01AM	Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline (Zacks)
Feb-07-23 05:01PM	Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight (TipRanks)
Feb-02-23 07:30AM	Relay Therapeutics to Participate in Guggenheim Healthcare Talks \| Oncology Day (GlobeNewswire)
Jan-13-23 11:11AM	Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock? (Zacks)
Jan-03-23 07:30AM	Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 08:53AM	Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Intrinsic Value Is Potentially 23% Below Its Share Price (Simply Wall St.)
Nov-24-22 08:02AM	Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely? (Simply Wall St.)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
Nov-07-22 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-03-22 06:35PM	Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-27-22 04:05PM	Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-14-22 10:14AM	Relay Therapeutics (NASDAQ:RLAY shareholders incur further losses as stock declines 11% this week, taking one-year losses to 44% (Simply Wall St.)
Sep-26-22 07:30AM	Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference (GlobeNewswire)

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rahmer Peter	See remarks	Oct 28 '24	Sale	6.06	1,621	9,823	390,063	Oct 30 04:09 PM
Catinazzo Thomas	Chief Financial Officer	Oct 28 '24	Sale	6.06	6,802	41,220	306,391	Oct 30 04:09 PM
Catinazzo Thomas	Chief Financial Officer	Oct 29 '24	Sale	5.95	2,300	13,685	304,091	Oct 30 04:09 PM
Bergstrom Donald A	President, R&D	Oct 28 '24	Sale	6.06	2,688	16,289	520,745	Oct 30 04:08 PM
Adams Brian	Chief Legal Officer	Oct 28 '24	Sale	6.06	1,632	9,890	321,907	Oct 30 04:07 PM
THOMAS J CATINAZZO	Officer	Oct 29 '24	Proposed Sale	5.95	2,300	13,685		Oct 29 04:04 PM
THOMAS J CATINAZZO	Officer	Oct 28 '24	Proposed Sale	6.06	5,105	30,936		Oct 28 04:05 PM
Rahmer Peter	See remarks	Sep 27 '24	Sale	7.51	245	1,840	391,684	Oct 01 04:07 PM
Catinazzo Thomas	Chief Financial Officer	Sep 27 '24	Sale	7.46	6,457	48,184	313,193	Oct 01 04:07 PM
Bergstrom Donald A	President, R&D	Sep 27 '24	Sale	7.51	648	4,866	523,433	Oct 01 04:07 PM
Adams Brian	Chief Legal Officer	Sep 27 '24	Sale	7.51	295	2,215	323,539	Oct 01 04:06 PM
THOMAS J CATINAZZO	Officer	Sep 27 '24	Proposed Sale	7.46	6,162	45,977		Sep 27 04:27 PM
Catinazzo Thomas	Chief Financial Officer	Jul 29 '24	Sale	8.56	10,780	92,316	319,650	Jul 31 06:43 PM
Rahmer Peter	See remarks	Jul 30 '24	Sale	8.28	15,128	125,260	405,637	Jul 31 06:43 PM
Rahmer Peter	See remarks	Jul 29 '24	Sale	8.54	13,523	115,543	420,765	Jul 31 06:43 PM
Rahmer Peter	See remarks	Jul 31 '24	Sale	8.19	13,708	112,269	391,929	Jul 31 06:43 PM
Bergstrom Donald A	President, R&D	Jul 29 '24	Sale	8.85	2,698	23,877	524,081	Jul 31 06:42 PM
Adams Brian	Chief Legal Officer	Jul 29 '24	Sale	8.85	1,638	14,496	323,834	Jul 31 06:42 PM
PETER J RAHMER	Officer	Jul 31 '24	Proposed Sale	8.19	13,708	112,245		Jul 31 04:06 PM
PETER J RAHMER	Officer	Jul 30 '24	Proposed Sale	8.28	15,128	125,290		Jul 30 04:19 PM
Patel Sanjiv	President and CEO	Jul 25 '24	Option Exercise	5.04	50,000	252,000	816,130	Jul 29 06:37 PM
Patel Sanjiv	President and CEO	Jul 26 '24	Option Exercise	5.04	36,706	184,998	802,836	Jul 29 06:37 PM
Patel Sanjiv	President and CEO	Jul 25 '24	Sale	9.16	50,000	458,000	766,130	Jul 29 06:37 PM
Patel Sanjiv	President and CEO	Jul 26 '24	Sale	9.07	36,706	332,923	766,130	Jul 29 06:37 PM
THOMAS J CATINAZZO	Officer	Jul 29 '24	Proposed Sale	8.51	9,078	77,243		Jul 29 04:29 PM
PETER J RAHMER	Officer	Jul 29 '24	Proposed Sale	8.51	12,164	103,488		Jul 29 04:24 PM
SANJIV PATEL	Officer	Jul 26 '24	Proposed Sale	9.07	36,706	332,769		Jul 26 04:47 PM
Bergstrom Donald A	President, R&D	Jun 27 '24	Sale	6.26	648	4,056	526,779	Jul 01 04:42 PM
Rahmer Peter	See remarks	Jun 27 '24	Sale	6.26	245	1,534	432,180	Jul 01 04:41 PM
Catinazzo Thomas	Chief Financial Officer	Jun 27 '24	Sale	6.24	9,373	58,493	330,430	Jul 01 04:41 PM
Adams Brian	Chief Legal Officer	Jun 27 '24	Sale	6.26	295	1,847	325,472	Jul 01 04:38 PM
Rubin Jami	Director	Jun 10 '24	Option Exercise	5.04	42,242	212,900	67,242	Jun 12 04:06 PM
Rahmer Peter	See remarks	Jun 04 '24	Sale	6.64	40,595	269,551	452,875	Jun 05 08:01 PM
Rahmer Peter	See remarks	Jun 05 '24	Sale	7.06	20,450	144,377	432,425	Jun 05 08:01 PM
Rahmer Peter	See remarks	Jun 03 '24	Sale	6.47	19,864	128,520	493,470	Jun 05 08:01 PM
Rahmer Peter	See remarks	Apr 29 '24	Sale	6.38	1,345	8,581	513,334	Apr 29 08:36 PM
Adams Brian	Chief Legal Officer	Apr 29 '24	Sale	6.38	1,623	10,355	325,767	Apr 29 08:33 PM
Catinazzo Thomas	Chief Financial Officer	Apr 29 '24	Sale	6.38	1,695	10,814	339,803	Apr 29 08:31 PM
Bergstrom Donald A	President, R&D	Apr 29 '24	Sale	6.38	2,686	17,137	527,427	Apr 29 08:30 PM
Catinazzo Thomas	Chief Financial Officer	Mar 27 '24	Sale	7.70	348	2,680	341,498	Mar 29 04:15 PM
Bergstrom Donald A	President, R&D	Mar 27 '24	Sale	7.70	765	5,890	530,113	Mar 29 04:15 PM
Rahmer Peter	See remarks	Mar 27 '24	Sale	7.70	298	2,295	514,679	Mar 29 04:15 PM
Adams Brian	Chief Legal Officer	Mar 27 '24	Sale	7.70	348	2,680	327,390	Mar 29 04:15 PM
Rahmer Peter	See remarks	Jan 29 '24	Sale	9.64	1,651	15,916	514,977	Jan 31 04:14 PM
Catinazzo Thomas	Chief Financial Officer	Jan 29 '24	Sale	9.64	2,005	19,328	341,846	Jan 31 04:11 PM
Bergstrom Donald A	President, R&D	Jan 29 '24	Sale	9.64	3,178	30,636	530,878	Jan 31 04:08 PM
Adams Brian	Chief Legal Officer	Jan 29 '24	Sale	9.64	1,929	18,596	327,738	Jan 31 04:05 PM
Rahmer Peter	See remarks	Dec 27 '23	Sale	11.51	244	2,808	316,628	Dec 29 04:26 PM
Catinazzo Thomas	Chief Financial Officer	Dec 27 '23	Sale	11.51	294	3,384	143,851	Dec 29 04:22 PM
Bergstrom Donald A	President, R&D	Dec 27 '23	Sale	11.51	977	11,245	234,056	Dec 29 04:17 PM
Adams Brian	Chief Legal Officer	Dec 27 '23	Sale	11.51	294	3,384	129,667	Dec 29 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLAY

Relay Therapeutics Inc

Upgrade your FINVIZ experience